Form 4: Eli Lilly director buys 215.327 shares at $1,021.7

Eli Lilly director Kimberly H. Johnson acquired 215.327 common shares on November 17, 2025 at $1,021.7 each, lifting her direct holdings to 3,264.731 shares.

Summary

• Director Kimberly H. Johnson acquired 215.327 shares of Eli Lilly common stock on 11/17/2025.
• Transaction Code: A (grant, award, or other acquisition, non-derivative).
• Price per share: $1,021.7; estimated transaction value ≈ $220,009.6.
• Beneficial ownership after the transaction: 3,264.731 shares, held directly (D).
• No derivative securities were reported.
• Form was signed on 11/18/2025 by Jonathan Groff as attorney-in-fact for Johnson.

Sentiment

Score: 6

Explanation: Insider acquisition by a director is a constructive signal, but the event is modest in size relative to company scale and does not change fundamentals.

Positives

• Insider purchase by a board director signals personal alignment with shareholders.
• Post-transaction direct ownership increased to 3,264.731 shares.
• No sales or derivative dispositions reported alongside the acquisition.

Negatives

• No information on company operating performance, outlook, or financial results disclosed in this report.

Future Outlook

No forward-looking statements or guidance provided.

Industry Context

Insider purchases in large-cap pharmaceuticals are typically viewed as modestly positive sentiment signals; however, single transactions of this size rarely move shares of mega-cap companies like Eli Lilly given their scale and liquidity.

Comparison to Industry Standards

• The transaction size (≈$220k) is consistent with typical director-level insider acquisitions seen across large-cap pharma, where individual purchases often range in the low six figures.
• Given Eli Lilly’s high share price, the share count acquired (215.327) is lower than peers for a similar dollar value, which is typical when comparing to companies like Pfizer (PFE) or Merck (MRK) with lower nominal share prices.
• Absence of concurrent sales aligns with a more favorable signal compared to mixed buy/sell patterns sometimes observed at peers.

Stakeholder Impact

• Shareholders may view the insider purchase as a positive governance and confidence signal.
• No dilution or capital structure impact implied by this transaction.
• No operational or strategic changes indicated.

Key Dates

Recommendation

The insider purchase is a mild positive sentiment indicator, but the transaction does not provide new information on earnings, pipeline, or strategy. Without incremental fundamentals, the appropriate stance based solely on this report is Hold.

Keywords

Eli Lilly, LLY, insider buying, Form 4, director purchase, beneficial ownership, pharmaceuticals, equity award, corporate governance